AI-Based Mobile Intervention on Medication Non-Adherence and Transition
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in
| Condition(s) | Epilepsy, Seizure |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints. |
| Who can participate | Inclusion Criteria: * Diagnosed with epilepsy * Currently prescribed anti-seizure medicine (ASMs) * Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) * Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study * Are between 18-24 years old and able to provide informed consent * Able to read, speak, and write in English * Resides in Florida * Receive outpatient medical services Exclusion Criteria: * They do not own a mobile device with internet access. * They have a history of s |
| Ages | 14 Years to 24 Years |
| Sex | All |
| Lead sponsor | University of Central Florida |
| Locations | Orlando, Florida, United States; Orlando, Florida, United States |
| Start date | 2026-05 |
| NCT ID | NCT07445074 |
| Official listing | https://clinicaltrials.gov/study/NCT07445074 |